Network meta-analysis shows brexpiprazole improves agitation outcomes in Alzheimer’s disease, with 2 mg offering optimal balance between efficacy and tolerability, while higher doses increase adverse events without added serious safety risk.

• 61
• 0
• 0
• 0

Study describes development and validation of a brief caregiver-completed screener for agitation in Alzheimer’s dementia, demonstrating acceptable agreement with IPA criteria and supporting earlier recognition, assessment, and treatment planning.

• 0
• 0
• 0
• 0

This study links environmental triggers—light, sound variability, time, and location—to specific agitation subtypes in dementia. Findings support predictive models and timely interventions to reduce agitation, improving patient quality of life and caregiver burden.

• 6
• 0
• 0
• 0